Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.

Selnick HG, Hess JF, Tang C, Liu K, Schachter JB, Ballard JE, Marcus J, Klein DJ, Wang X, Pearson M, Savage MJ, Kaul R, Li TS, Vocadlo DJ, Zhou Y, Zhu Y, Mu C, Wang Y, Wei Z, Bai C, Duffy JL, McEachern EJ.

J Med Chem. 2019 Nov 27;62(22):10062-10097. doi: 10.1021/acs.jmedchem.9b01090. Epub 2019 Sep 29.

PMID:
31487175
2.

Pharmacogenetic neuronal stimulation increases human tau pathology and trans-synaptic spread of tau to distal brain regions in mice.

Schultz MK Jr, Gentzel R, Usenovic M, Gretzula C, Ware C, Parmentier-Batteur S, Schachter JB, Zariwala HA.

Neurobiol Dis. 2018 Oct;118:161-176. doi: 10.1016/j.nbd.2018.07.003. Epub 2018 Jul 7.

PMID:
30049665
3.

Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy.

Wang X, Smith K, Pearson M, Hughes A, Cosden ML, Marcus J, Hess JF, Savage MJ, Rosahl T, Smith SM, Schachter JB, Uslaner JM.

PLoS One. 2018 Apr 6;13(4):e0195486. doi: 10.1371/journal.pone.0195486. eCollection 2018.

4.

Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging.

Liang SH, Chen JM, Normandin MD, Chang JS, Chang GC, Taylor CK, Trapa P, Plummer MS, Para KS, Conn EL, Lopresti-Morrow L, Lanyon LF, Cook JM, Richter KE, Nolan CE, Schachter JB, Janat F, Che Y, Shanmugasundaram V, Lefker BA, Enerson BE, Livni E, Wang L, Guehl NJ, Patnaik D, Wagner FF, Perlis R, Holson EB, Haggarty SJ, El Fakhri G, Kurumbail RG, Vasdev N.

Angew Chem Int Ed Engl. 2016 Aug 8;55(33):9601-5. doi: 10.1002/anie.201603797. Epub 2016 Jun 29.

5.

Detecting tau in serum of transgenic animal models after tau immunotherapy treatment.

d'Abramo C, Acker CM, Schachter JB, Terracina G, Wang X, Forest SK, Davies P.

Neurobiol Aging. 2016 Jan;37:58-65. doi: 10.1016/j.neurobiolaging.2015.09.017. Epub 2015 Oct 21.

6.

Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance.

Lonskaya I, Hebron ML, Desforges NM, Schachter JB, Moussa CE.

J Mol Med (Berl). 2014 Apr;92(4):373-86. doi: 10.1007/s00109-013-1112-3. Epub 2013 Dec 13.

7.

High throughput monitoring of amyloid-β(42) assembly into soluble oligomers achieved by sensitive conformation state-dependent immunoassays.

Zhao WQ, Toolan D, Hepler RW, Wolfe AL, Yu Y, Price E, Uebele VN, Schachter JB, Reynolds IJ, Renger JJ, McCampbell A, Ray WJ.

J Alzheimers Dis. 2011;25(4):655-69. doi: 10.3233/JAD-2011-102022.

PMID:
21483096
8.

Design, synthesis, and in vivo characterization of a novel series of tetralin amino imidazoles as γ-secretase inhibitors: discovery of PF-3084014.

Brodney MA, Auperin DD, Becker SL, Bronk BS, Brown TM, Coffman KJ, Finley JE, Hicks CD, Karmilowicz MJ, Lanz TA, Liston D, Liu X, Martin BA, Nelson RB, Nolan CE, Oborski CE, Parker CP, Richter KE, Pozdnyakov N, Sahagan BG, Schachter JB, Sokolowski SA, Tate B, Wood DE, Wood KM, Van Deusen JW, Zhang L.

Bioorg Med Chem Lett. 2011 May 1;21(9):2637-40. doi: 10.1016/j.bmcl.2010.12.118. Epub 2010 Dec 30.

PMID:
21269827
9.

Diamide amino-imidazoles: a novel series of γ-secretase inhibitors for the treatment of Alzheimer's disease.

Brodney MA, Auperin DD, Becker SL, Bronk BS, Brown TM, Coffman KJ, Finley JE, Hicks CD, Karmilowicz MJ, Lanz TA, Liston D, Liu X, Martin BA, Nelson RB, Nolan CE, Oborski CE, Parker CP, Richter KE, Pozdnyakov N, Sahagan BG, Schachter JB, Sokolowski SA, Tate B, Van Deusen JW, Wood DE, Wood KM.

Bioorg Med Chem Lett. 2011 May 1;21(9):2631-6. doi: 10.1016/j.bmcl.2010.12.117. Epub 2010 Dec 30.

PMID:
21269825
10.

Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer's disease.

Helal CJ, Kang Z, Lucas JC, Gant T, Ahlijanian MK, Schachter JB, Richter KE, Cook JM, Menniti FS, Kelly K, Mente S, Pandit J, Hosea N.

Bioorg Med Chem Lett. 2009 Oct 1;19(19):5703-7. doi: 10.1016/j.bmcl.2009.08.019. Epub 2009 Aug 8.

PMID:
19700321
11.
12.

Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models.

Lanz TA, Salatto CT, Semproni AR, Marconi M, Brown TM, Richter KE, Schmidt K, Nelson FR, Schachter JB.

Biochem Pharmacol. 2008 Mar 1;75(5):1093-103. Epub 2007 Nov 12.

PMID:
18076866
13.

Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia.

Planel E, Richter KE, Nolan CE, Finley JE, Liu L, Wen Y, Krishnamurthy P, Herman M, Wang L, Schachter JB, Nelson RB, Lau LF, Duff KE.

J Neurosci. 2007 Mar 21;27(12):3090-7.

14.

Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.

Lanz TA, Karmilowicz MJ, Wood KM, Pozdnyakov N, Du P, Piotrowski MA, Brown TM, Nolan CE, Richter KE, Finley JE, Fei Q, Ebbinghaus CF, Chen YL, Spracklin DK, Tate B, Geoghegan KF, Lau LF, Auperin DD, Schachter JB.

J Pharmacol Exp Ther. 2006 Nov;319(2):924-33. Epub 2006 Aug 18.

PMID:
16920992
16.

Cdk5 as a drug target for the treatment of Alzheimer's disease.

Lau LF, Seymour PA, Sanner MA, Schachter JB.

J Mol Neurosci. 2002 Dec;19(3):267-73. Review.

PMID:
12540052
17.

Tau protein phosphorylation as a therapeutic target in Alzheimer's disease.

Lau LF, Schachter JB, Seymour PA, Sanner MA.

Curr Top Med Chem. 2002 Apr;2(4):395-415. Review.

PMID:
11966463
18.

Agonist action of adenosine triphosphates at the human P2Y1 receptor.

Palmer RK, Boyer JL, Schachter JB, Nicholas RA, Harden TK.

Mol Pharmacol. 1998 Dec;54(6):1118-23.

PMID:
9855642
19.

Fidelity in functional coupling of the rat P2Y1 receptor to phospholipase C.

Schachter JB, Boyer JL, Li Q, Nicholas RA, Harden TK.

Br J Pharmacol. 1997 Nov;122(6):1021-4.

20.

HEK293 human embryonic kidney cells endogenously express the P2Y1 and P2Y2 receptors.

Schachter JB, Sromek SM, Nicholas RA, Harden TK.

Neuropharmacology. 1997 Sep;36(9):1181-7.

PMID:
9364473
21.

A mutational analysis of residues essential for ligand recognition at the human P2Y1 receptor.

Jiang Q, Guo D, Lee BX, Van Rhee AM, Kim YC, Nicholas RA, Schachter JB, Harden TK, Jacobson KA.

Mol Pharmacol. 1997 Sep;52(3):499-507.

22.

The 6H1 orphan receptor, claimed to be the p2y5 receptor, does not mediate nucleotide-promoted second messenger responses.

Li Q, Schachter JB, Harden TK, Nicholas RA.

Biochem Biophys Res Commun. 1997 Jul 18;236(2):455-60.

PMID:
9240460
23.

Lack of nucleotide-promoted second messenger signaling responses in 1321N1 cells expressing the proposed P2Y receptor, p2y7.

Herold CL, Li Q, Schachter JB, Harden TK, Nicholas RA.

Biochem Biophys Res Commun. 1997 Jun 27;235(3):717-21.

PMID:
9207227
25.

Identification of competitive antagonists of the P2Y1 receptor.

Boyer JL, Romero-Avila T, Schachter JB, Harden TK.

Mol Pharmacol. 1996 Nov;50(5):1323-9.

PMID:
8913364
27.

Second messenger cascade specificity and pharmacological selectivity of the human P2Y1-purinoceptor.

Schachter JB, Li Q, Boyer JL, Nicholas RA, Harden TK.

Br J Pharmacol. 1996 May;118(1):167-73.

29.
31.

Competitive regulation of phospholipase C responses by cAMP and calcium.

Schachter JB, Ivins JK, Pittman RN, Wolfe BB.

Mol Pharmacol. 1992 Mar;41(3):577-86.

PMID:
1312217

Supplemental Content

Loading ...
Support Center